A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)

Therapeutic options to inhibit the growth and spread of neuroendocrine (NE) gastrointestinal tumours are still limited. Since gefitinib (4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline), an inhibitor of epidermal growth factor receptor-sensitive tyrosine kinase (EGFR-TK), h...

Descripción completa

Detalles Bibliográficos
Autores principales: Höpfner, M, Sutter, A P, Gerst, B, Zeitz, M, Scherübl, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394425/
https://www.ncbi.nlm.nih.gov/pubmed/14583782
http://dx.doi.org/10.1038/sj.bjc.6601346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394425/
https://www.ncbi.nlm.nih.gov/pubmed/14583782
http://dx.doi.org/10.1038/sj.bjc.6601346

Ejemplares similares